StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Pacira BioSciences's EV/EBITDA was 14.9× on Nov 11, 2026, against 8.6× a year earlier. Over the last 5 years it ranged from 1.7× to 248.3×, with a median of 11.5×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202614.9×+5.5
2025Dec 31, 20259.4×−28.0
2024Dec 31, 202437.4×+27.3
2023Dec 29, 202310.1×+0.4
2022Dec 30, 20229.7×−6.2
2021Dec 31, 202115.9×−26.0
2020Dec 31, 202041.8×+0.8
2019Dec 31, 201941.0×−14.4
2018Dec 31, 201855.4×−62.0
2016Oct 31, 2016117.4×+3.6
2015Dec 31, 2015113.8×–

More Pacira BioSciences figures

See a number that looks wrong?